Literature DB >> 2854336

Flavivirus vaccines.

J R Stephenson1.   

Abstract

Diseases caused by flavivirus infection have been a scourge of mankind for over three centuries; with yellow fever, dengue fever and Russian spring-summer encephalitis causing epidemics resulting in thousands of fatalities. Due to the development of a safe and efficacious live-attenuated vaccine against yellow fever, this disease is no longer such a threat in countries where adequate vaccination is practised. A similarly safe and efficacious inactivated vaccine against central-European tick-borne encephalitis has also been developed and this has drastically reduced the incidence of this disease in many countries where it is endemic. In spite of these successes, the development of vaccines against other pathogenic flaviviruses, causing diseases such as dengue fever and Russian spring-summer encephalitis, have not been successful. This review attempts to summarize the development of flavivirus vaccines to date and identify areas for future improvements. Problems associated with designing flavivirus vaccines are discussed and the advantages and disadvantages of future strategies for vaccine development are considered.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854336     DOI: 10.1016/0264-410x(88)90095-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.

Authors:  S Bhardwaj; M Holbrook; R E Shope; A D Barrett; S J Watowich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

Review 3.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.

Authors:  R J Phillpotts; K Venugopal; T Brooks
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

5.  Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus.

Authors:  Samantha Brandler; Marianne Lucas-Hourani; Arnaud Moris; Marie-Pascale Frenkiel; Chantal Combredet; Michèle Février; Hugues Bedouelle; Olivier Schwartz; Philippe Desprès; Frédéric Tangy
Journal:  PLoS Negl Trop Dis       Date:  2007-12-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.